Effects of P2Y12 Receptor Antagonists Beyond Platelet Inhibition--comparison of Ticagrelor with Thienopyridines

Overview

Journal Br J Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2016 Jan 14

PMID 26758983

Citations 45

Authors

Sven Nylander

Rainer Schulz

Affiliations

Soon will be listed here.

Abstract

The effect and clinical benefit of P2Y12 receptor antagonists may not be limited to platelet inhibition and the prevention of arterial thrombus formation. Potential additional effects include reduction of the pro-inflammatory role of activated platelets and effects related to P2Y12 receptor inhibition on other cells apart from platelets. P2Y12 receptor antagonists, thienopyridines and ticagrelor, differ in their mode of action being prodrugs instead of direct acting and irreversibly instead of reversibly binding to P2Y12 . These key differences may provide different potential when it comes to additional effects. In addition to P2Y12 receptor blockade, ticagrelor is unique in having the only well-documented additional target of inhibition, the equilibrative nucleoside transporter 1. The current review will address the effects of P2Y12 receptor antagonists beyond platelets and the protection against arterial thrombosis. The discussion will include the potential for thienopyridines and ticagrelor to mediate anti-inflammatory effects, to conserve vascular function, to affect atherosclerosis, to provide cardioprotection and to induce dyspnea.

Citing Articles

Randomised Placebo-Controlled Pilot Trial Evaluating the Anti-Anginal Efficacy of Ticagrelor in Patients with Angina with Nonobstructive Coronary Arteries and Coronary Slow Flow Phenomenon.

Pasupathy S, Tavella R, Zeitz C, Edwards S, Worthley M, Arstall M J Clin Med. 2024; 13(17).

PMID: 39274447 PMC: 11395883. DOI: 10.3390/jcm13175235.

Ticagrelor, but Not Clopidogrel, Attenuates Hepatic Steatosis in a Model of Metabolic Dysfunction-Associated Steatotic Liver Disease.

Lee E, Lee S, Oh J, Kim H, Saeed W, Kim H Nutrients. 2024; 16(7).

PMID: 38612954 PMC: 11013111. DOI: 10.3390/nu16070920.

Off-Target Effects of P2Y12 Receptor Inhibitors: Focus on Early Myocardial Fibrosis Modulation.

Lofrumento F, Irrera N, Licordari R, Perfetti S, Nasso E, Liotta P Int J Mol Sci. 2023; 24(24).

PMID: 38139379 PMC: 10743395. DOI: 10.3390/ijms242417546.

The effect of ticagrelor on coronary microvascular function after PCI in patients with ACS compared to clopidogrel: A systematic review and meta-analysis.

Qiu X, Li X, Fu K, Chen W, Chen W PLoS One. 2023; 18(8):e0289243.

PMID: 37643179 PMC: 10464986. DOI: 10.1371/journal.pone.0289243.

The Role of Antiplatelet in the Management of Sickle Cell Disease Patients.

Naramreddy S, Varma A, Taksande A, Meshram R Cureus. 2023; 15(7):e42058.

PMID: 37602132 PMC: 10434724. DOI: 10.7759/cureus.42058.

References

Azar R, Kassab R, Zoghbi A, Aboujaoude S, El-Osta H, Ghorra P . Effects of clopidogrel on soluble CD40 ligand and on high-sensitivity C-reactive protein in patients with stable coronary artery disease. Am Heart J. 2006; 151(2):521.e1-521.e4. DOI: 10.1016/j.ahj.2005.10.021. View

Siasos G, Oikonomou E, Zaromitidou M, Kioufis S, Kokkou E, Mourouzis K . Clopidogrel response variability is associated with endothelial dysfunction in coronary artery disease patients receiving dual antiplatelet therapy. Atherosclerosis. 2015; 242(1):102-8. DOI: 10.1016/j.atherosclerosis.2015.07.009. View

Alexander S, Fabbro D, Kelly E, Marrion N, Peters J, Benson H . The Concise Guide to PHARMACOLOGY 2015/16: Enzymes. Br J Pharmacol. 2015; 172(24):6024-109. PMC: 4718211. DOI: 10.1111/bph.13354. View

Schnorbus B, Daiber A, Jurk K, Warnke S, Konig J, Krahn U . Effects of clopidogrel, prasugrel and ticagrelor on endothelial function, inflammatory and oxidative stress parameters and platelet function in patients undergoing coronary artery stenting for an acute coronary syndrome. A randomised, prospective,.... BMJ Open. 2014; 4(5):e005268. PMC: 4025413. DOI: 10.1136/bmjopen-2014-005268. View

Teng B, Smith J, Rosenfeld M, Robinet P, Davis M, Morrison R . A₁ adenosine receptor deficiency or inhibition reduces atherosclerotic lesions in apolipoprotein E deficient mice. Cardiovasc Res. 2014; 102(1):157-65. PMC: 3958624. DOI: 10.1093/cvr/cvu033. View

Liverani E, Rico M, Garcia A, Kilpatrick L, Kunapuli S . Prasugrel metabolites inhibit neutrophil functions. J Pharmacol Exp Ther. 2012; 344(1):231-43. PMC: 3533408. DOI: 10.1124/jpet.112.195883. View

Frelinger 3rd A, Jakubowski J, Li Y, Barnard M, Fox M, Linden M . The active metabolite of prasugrel inhibits ADP-stimulated thrombo-inflammatory markers of platelet activation: Influence of other blood cells, calcium, and aspirin. Thromb Haemost. 2007; 98(1):192-200. View

Vivekananthan D, Bhatt D, Chew D, Zidar F, Chan A, Moliterno D . Effect of clopidogrel pretreatment on periprocedural rise in C-reactive protein after percutaneous coronary intervention. Am J Cardiol. 2004; 94(3):358-60. DOI: 10.1016/j.amjcard.2004.04.035. View

Totani L, DellElba G, Martelli N, Di Santo A, Piccoli A, Amore C . Prasugrel inhibits platelet-leukocyte interaction and reduces inflammatory markers in a model of endotoxic shock in the mouse. Thromb Haemost. 2012; 107(6):1130-40. DOI: 10.1160/TH11-12-0867. View

10.

Baaten C, Veenstra L, Wetzels R, van Geffen J, Swieringa F, de Witt S . Gradual increase in thrombogenicity of juvenile platelets formed upon offset of prasugrel medication. Haematologica. 2015; 100(9):1131-8. PMC: 4800712. DOI: 10.3324/haematol.2014.122457. View

11.

Yusuf S, Zhao F, Mehta S, Chrolavicius S, Tognoni G, Fox K . Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345(7):494-502. DOI: 10.1056/NEJMoa010746. View

12.

Lindholm D, Storey R, Christersson C, Halvorsen S, Grove E, Braun O . Design and rationale of TROCADERO: A TRial Of Caffeine to Alleviate DyspnEa Related to ticagrelOr. Am Heart J. 2015; 170(3):465-70. DOI: 10.1016/j.ahj.2015.06.014. View

13.

Montalescot G, Sideris G, Meuleman C, Bal-Dit-Sollier C, Lellouche N, Steg P . A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing.... J Am Coll Cardiol. 2006; 48(5):931-8. DOI: 10.1016/j.jacc.2006.04.090. View

14.

Woo J, Kim W, Jang H, Kim J, Kim W, Kim K . Effect of platelet reactivity, endothelial function, and inflammatory status on outcomes in patients with stable angina pectoris on clopidogrel therapy. Am J Cardiol. 2014; 113(5):786-92. DOI: 10.1016/j.amjcard.2013.11.025. View

15.

Diehl P, Olivier C, Halscheid C, Helbing T, Bode C, Moser M . Clopidogrel affects leukocyte dependent platelet aggregation by P2Y12 expressing leukocytes. Basic Res Cardiol. 2009; 105(3):379-87. DOI: 10.1007/s00395-009-0073-8. View

16.

Yeh E, Khan B . The potential role of antiplatelet agents in modulating inflammatory markers in atherothrombosis. J Thromb Haemost. 2006; 4(11):2308-16. DOI: 10.1111/j.1538-7836.2006.02202.x. View

17.

Molero L, Lopez-Farre A, Mateos-Caceres P, Fernandez-Sanchez R, Maestro M, Silva J . Effect of clopidogrel on the expression of inflammatory markers in rabbit ischemic coronary artery. Br J Pharmacol. 2005; 146(3):419-24. PMC: 1576286. DOI: 10.1038/sj.bjp.0706340. View

18.

Bjorkman J, Zachrisson H, Forsberg G, von Bahr H, Hansson G, Warner T . High-dose aspirin in dogs increases vascular resistance with limited additional anti-platelet effect when combined with potent P2Y12 inhibition. Thromb Res. 2013; 131(4):313-9. DOI: 10.1016/j.thromres.2013.01.029. View

19.

Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M . Clopidogrel improves systemic endothelial nitric oxide bioavailability in patients with coronary artery disease: evidence for antioxidant and antiinflammatory effects. Arterioscler Thromb Vasc Biol. 2006; 26(7):1648-52. DOI: 10.1161/01.ATV.0000225288.74170.dc. View

20.

Gurbel P, Tantry U . Inhibited and Uninhibited Platelet Deposition Within a Thrombus: Does It Depend on the Antiplatelet Drug?. Arterioscler Thromb Vasc Biol. 2015; 35(10):2081-2. DOI: 10.1161/ATVBAHA.115.306371. View